Turn Therapeutics’ stock jumps on AD data and trial expansion

More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development. More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development. GlobalData estimates that the AD market will grow from $8.5bn in 2023 to $22.4bn by 2033 across the seven major markets. Credit: savitskaya iryna / Shutterstock.com Turn Therapeutics’ stock has jumped by 26% after its atopic dermatitis (AD) candidate boasted clinically meaningful efficacy in a Phase II trial, prompting the company to expand the study. The Phase II trial (NCT07355075) is evaluating GX-03, which…

Source: Clinical Trials Arena